Clinical trials: Ticagrelor
Acute Coronary Syndrome
Efficacy and Safety Study of Ticagrelor
The purpose of this study is to compare the efficacy and safety of ticagrelor with clopidogrel
- Trial name
- NCT01812330
- Testing
- Clopidogrel, Ticagrelor
- Where
- China
- Volunteers
- 180 people
- Sponsor
- General Hospital of Chinese Armed Police Forces
Acute Coronary Syndromes, Non ST Elevation Myocardial Infarction
Sub Lingual Versus Traditional Oral Administration of Ticagrelor in Acute Coronary Syndrome/Non ST-elevation Myocardial Infarction - A Platelet Reactivity Study
Our goal is to examine sub lingual versus traditional oral administration of ticagrelor in ACS/non ST-elevation Myocardial Infarction (NSTEMI) patients on platelet reactivity.
- Trial name
- NCT02402400
- Testing
- Sub Lingual Ticagrelor
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Sheba Medical Center
Acute Coronary Syndrome
The Effect of Clopidogrel and Ticagrelor With and Without Acetylsalicylic Acid (ASA) on Hemostatic System Activation at the Site of Plug Formation in Vivo in Man
Background: Coronary heart disease is the most common cause of death in industrialized countries. Revascularisation by percutaneous coronary angioplasty or thrombolysis is the main principle for treatment of the acute coronary…
- Trial name
- NCT02120092
- Testing
- Clopidogrel, Ticagrelor, ASA
- Where
- Austria
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Healthy
Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination.
Study conducted to determine and compare the relative bioavailability of two solid oral formulations (reference versus test) of the non-fixed combination of Ticagrelor 90 mg (Brilinta by AstraZeneca S.A.
- Trial name
- NCT07444164
- Testing
- A1: Ticagrelor / Acetylsalicylic acid in fixed dose combination capsule. (Laboratorios Silanes S.A. de C.V.), A2: Ticagrelor (BRILINTA®, AstraZeneca S.A. de C.V.) A3: Acetylsalicylic Acid (ASPIRINA JUNIOR®, Bayer de México S.A. de C.V.)
- Where
- Mexico
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Optimized Antiplatelet Therapy on the Prognosis of ACS Patients With Non-predominant Coronary Artery Disease After PCI
The study is to evaluate the effect of optimized 12-month step-down antiplatelet therapy (APT) compared with standard 12-month dual antiplatelet therapy in clinical net adverse events, cardiovascular and cerebrovascular adverse…
- Trial name
- NCT04338919
- Testing
- Percutaneous coronary intervention, Ticagrelor plus aspirin
- Where
- China
- Volunteers
- 2,020 people
- Sponsor
- Fujian Medical University
Acute Coronary Syndrome
Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome
The first aim of the study is to prove that after starting the therapy with crushed tablets, the platelet inhibition will be as expected after starting therapy with intact tablets. Gurbel et al.
- Trial name
- ticagrelor (NCT02341729)
- Testing
- ticagrelor
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- University Hospital, Ghent
Stable Coronary Artery Disease
A Pharmacodynamic Study With Ticagrelor in Hispanic Patients
The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in Hispanic patients with stable coronary artery disease.
- Trial name
- NCT01523366
- Testing
- Ticagrelor, Clopidogrel
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- AstraZeneca
Sickle Cell Disease
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
The purpose of the study is to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease
- Trial name
- HESTIA3 (NCT03615924)
- Testing
- Ticagrelor
- Where
- 55 sites in United States, Belgium and 14 more
- Volunteers
- 193 people
- Sponsor
- AstraZeneca
Unstable Angina Pectoris
Influence of Metoclopramide on Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris on Concomitant Treatment With Morphine
The purpose of this study is to evaluate differences in the pharmacokinetics and pharmacodynamics of ticagrelor and its active metabolite between patients who received ticagrelor and morphine followed by metoclopramide versus…
- Trial name
- NCT02939235
- Testing
- Crushed ticagrelor followed by morphine, Crushed ticagrelor, morphine,metoclopramide
- Where
- Poland
- Volunteers
- 32 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Senior Acute Coronary Syndrome Patients After PCI
A Study of Low Dose vs Standard Ticagrelor on Platelet Function After Intervention for Acute Coronary Syndrome in Senior Patients
In this study, the investigates try to confirm our hypothesis that low dose ticagrelor(60mg) had similar anti-platelets function compared with the standard dose ticagrelor in senior （no less than 75 years old)acute coronary…
- Trial name
- NCT04307485
- Testing
- Ticagrelor
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Tong Ren Hospital
Coronary Artery Disease, Stable Angina
Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG
The primary objective of this study ist to test the hypothesis that ticagrelor is superior to Aspirin (ASA) fort he prevention of major cardio- and cerebrovascular events (MACCE) in patients undergoing artery bypass operation.
- Conditions
- Coronary Artery Disease, Stable Angina, Acute Coronary Syndrome
- Trial name
- TiCAB (NCT01755520)
- Testing
- Ticagrelor, Aspirin
- Where
- 29 sites in Austria, Germany and 1 more
- Volunteers
- 1,893 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Ischemic Stroke, Acute
Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke
Early antiplatelet therapy is promising for further improvement of functional prognosis on the basis of intravenous thrombolytic therapy.
- Trial name
- TAPIS (NCT06316570)
- Testing
- Early Dual Antiplatelet Therapy
- Where
- 60 sites in China
- Volunteers
- 1,382 people
- Sponsor
- Beijing Tiantan Hospital
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)
The purpose of the study is to assess the efficacy (prevention of vascular events) and safety (especially bleedings) of Ticagrelor (AZD6140) compared with Clopidogrel, both given on top of low dose aspirin, in Asian/Japanese…
- Trial name
- NCT01294462
- Testing
- Ticagrelor, Clopidogrel, Acetylsalicylic acid ASA
- Where
- 87 sites in Japan, South Korea and 1 more
- Volunteers
- 801 people
- Sponsor
- AstraZeneca
Stable Coronary Artery Disease
A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders
The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of…
- Trial name
- RESPOND (NCT00642811)
- Testing
- Ticagrelor, Clopidogrel, Aspirin
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Coronary Artery Disease
Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease
The recommended antiplatelet treatment regimen for patients affected by acute coronary syndromes (ACS) and those undergoing percutaneous coronary intervention (PCI) consists in the combination of aspirin and a P2Y12 receptor…
- Trial name
- SWAP-4 (NCT02287909)
- Testing
- Clopidogrel, Ticagrelor
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- University of Florida
Acute Coronary Syndrome, Myocardial Infarction
Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI
This randomized, controlled trial compares the anti-thrombotic effect of cangrelor and ticagrelor on platelet activity in patients with acute ST-elevation myocardial infarction.
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction
- Trial name
- CanTi (NCT03182855)
- Testing
- Ticagrelor, Cangrelor Tetrasodium
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- University of Aarhus
Kidney Failure, Chronic
Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects
A phase I, open-label study comparing the pharmacokinetics, pharmacodynamics, safety and tolerability of ticagrelor in hemodialysis patients to healthy subjects with normal renal function.
- Trial name
- NCT02022748
- Testing
- ticagrelor
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Coronary Heart Disease
Ticagrelor Versus Clopidogrel for CMD in Patients With AMI: A Retrospective Study Based on the Angio-IMR
Coronary microvascular dysfunction (CMD) is increasingly recognized as an important indicator for long-term prognosis in patients with acute myocardial infarction (AMI).
- Trial name
- NCT05978726
- Testing
- Dual antiplatelet therapy with aspirin and either ticagrelor or clopidogrel
- Where
- China
- Volunteers
- 325 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Atrial Fibrillation, Antithrombotic Therapy
Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI
More than 25% of patients referred for diagnostic coronary angiography and percutaneous coronary intervention (PCI) due to acute coronary syndrome (ACS) suffer from non-valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation, Antithrombotic Therapy, Acute Coronary Syndrome, Percutaneous Coronary Interventions
- Trial name
- ADONIS-PCI (NCT04695106)
- Testing
- Ticagrelor, Dabigatran Etexilate, Aspirin
- Where
- Poland
- Volunteers
- 1,194 people
- Sponsor
- Medical University of Gdansk
Sickle Cell Disease
PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4)
The purpose of this Phase I study is to investigate the pharmacokinetic properties of ticagrelor in pediatric patients from 0 to less than 24 months with sickle cell disease.
- Trial name
- HESTIA4 (NCT03492931)
- Testing
- Ticagrelor
- Where
- 8 sites in Belgium, Italy and 4 more
- Volunteers
- 21 people
- Sponsor
- AstraZeneca